2023-08-03 08:15:44 ET
- Virax Biolabs Group ( NASDAQ: VRAX ) on Thursday received another 180-day extension till January 29, 2024 to regain compliance with Nasdaq's minimum bid price requirement.
- On January 30, 2023, Nasdaq had provided notice to the company that based on the previous 30 consecutive business days, VRAX stock no longer met the minimum bid price per share requirement.
- The company was provided 180 calendar days, or until July 31, 2023, to regain compliance.
- Nasdaq has determined that the company is eligible for an additional 180 calendar day period to regain compliance.
- If at any time during this additional time period the closing bid price of the Company's security is at least $1 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation of compliance.
- VRAX +2.47% premarket to $0.41
- Source: Press Release
For further details see:
Virax Biolabs receives extension to regain Nasdaq compliance